SG10201402628VA - Specific Diarylhydantoin And Diarylthiohydantoin Compounds - Google Patents
Specific Diarylhydantoin And Diarylthiohydantoin CompoundsInfo
- Publication number
- SG10201402628VA SG10201402628VA SG10201402628VA SG10201402628VA SG10201402628VA SG 10201402628V A SG10201402628V A SG 10201402628VA SG 10201402628V A SG10201402628V A SG 10201402628VA SG 10201402628V A SG10201402628V A SG 10201402628VA SG 10201402628V A SG10201402628V A SG 10201402628VA
- Authority
- SG
- Singapore
- Prior art keywords
- diarylhydantoin
- specific
- diarylthiohydantoin compounds
- diarylthiohydantoin
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15511909P | 2009-02-24 | 2009-02-24 | |
| US15639809P | 2009-02-27 | 2009-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201402628VA true SG10201402628VA (en) | 2014-10-30 |
Family
ID=42665887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201402628VA SG10201402628VA (en) | 2009-02-24 | 2010-02-24 | Specific Diarylhydantoin And Diarylthiohydantoin Compounds |
| SG2011061066A SG173837A1 (en) | 2009-02-24 | 2010-02-24 | Specific diarylhydantoin and diarylthiohydantoin compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011061066A SG173837A1 (en) | 2009-02-24 | 2010-02-24 | Specific diarylhydantoin and diarylthiohydantoin compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8524755B2 (en) |
| EP (1) | EP2400847B1 (en) |
| JP (2) | JP2012518661A (en) |
| KR (1) | KR20110130439A (en) |
| CN (1) | CN102421291A (en) |
| AU (1) | AU2010218052A1 (en) |
| BR (1) | BRPI1007990A2 (en) |
| CA (1) | CA2753425A1 (en) |
| ES (1) | ES2535466T3 (en) |
| IL (1) | IL214800A0 (en) |
| MX (1) | MX2011008858A (en) |
| NZ (1) | NZ594741A (en) |
| RU (1) | RU2548918C2 (en) |
| SG (2) | SG10201402628VA (en) |
| WO (1) | WO2010099238A1 (en) |
| ZA (2) | ZA201106200B (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| NZ596260A (en) * | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP2416657A4 (en) * | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof |
| RS57309B1 (en) | 2010-02-16 | 2018-08-31 | Aragon Pharmaceuticals Inc | Androgen receptor modulators and uses thereof |
| AU2014271290C1 (en) * | 2010-02-16 | 2016-10-27 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| AU2016208310B2 (en) * | 2010-02-16 | 2017-10-05 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| EP2538785B1 (en) | 2010-02-24 | 2018-03-21 | Medivation Prostate Therapeutics LLC | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
| KR20140048106A (en) * | 2011-03-14 | 2014-04-23 | 더 유니버시티 오브 브리티쉬 콜롬비아 | Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer |
| CA2843417C (en) | 2011-07-29 | 2018-08-21 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
| WO2013067131A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Technologies, Inc. | Treatment methods |
| WO2013067151A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment methods using diarylthiohydantoin derivatives |
| EP2664325A1 (en) * | 2012-05-16 | 2013-11-20 | PregLem S.A. | Methods for preventing or treating androgen mediated diseases |
| MX371020B (en) | 2012-09-26 | 2020-01-13 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer. |
| JOP20200097A1 (en) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| WO2014167428A2 (en) * | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| CN104803919A (en) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | Preparation method of enzalutamide intermediate F |
| CN104844521B (en) * | 2014-02-13 | 2017-08-15 | 成都伊诺达博医药科技有限公司 | The synthetic method of the miscellaneous Shandong amine of antiprostate cancer grace |
| CN104844520B (en) * | 2014-02-13 | 2017-09-05 | 成都伊诺达博医药科技有限公司 | A kind of method for synthesizing the miscellaneous Shandong amine of grace |
| RU2557235C1 (en) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Substituted 2-thioxo-imidazolidin-4-one, and spiroanalogues thereof, anticancer active ingredient, pharmaceutical composition, medicinal product, method of treating prostate cancer |
| US10131636B2 (en) * | 2014-10-01 | 2018-11-20 | Laurus Labs Limited | Process for the preparation of Enzalutamide |
| WO2016094408A1 (en) | 2014-12-12 | 2016-06-16 | Medivation Prostate Therapeutics, Inc. | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
| TWI613194B (en) | 2015-06-10 | 2018-02-01 | 台灣神隆股份有限公司 | A novel process for preparing enzalutamide |
| TWI726969B (en) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | Substituted thiohydantoin derivatives as androgen receptor antagonists |
| WO2018007624A1 (en) * | 2016-07-08 | 2018-01-11 | Actavis Group Ptc Ehf | Enzalutamide derivatives for the treatment of prostate and breast cancer |
| CN107954936B (en) * | 2016-10-17 | 2021-03-19 | 海创药业股份有限公司 | Method for preparing deuterated imidazoldione compound |
| CN107501237B (en) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | Synthetic method of Apalutamide |
| KR20200070334A (en) | 2017-10-16 | 2020-06-17 | 아라곤 파마슈티컬스, 인코포레이티드 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| US20210386826A1 (en) | 2018-11-05 | 2021-12-16 | Pfizer Inc. | Combination for Treating Cancer |
| JP2023537595A (en) | 2020-08-13 | 2023-09-04 | ファイザー・インク | combination therapy |
| CA3201054A1 (en) | 2020-12-11 | 2022-06-16 | Yoon-Suk Lee | Novel compounds as androgen receptor and phosphodiesterase dual inhibitor |
| EP4313034A1 (en) | 2021-03-24 | 2024-02-07 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| CA3230630A1 (en) * | 2021-09-08 | 2023-03-16 | Curtis SWIFT | Analytical methods of assessing cytisine purity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5136332B1 (en) * | 1970-12-09 | 1976-10-07 | ||
| FR2715402B1 (en) * | 1994-01-05 | 1996-10-04 | Roussel Uclaf | New phenylimidazolines optionally substituted, their process and preparation intermediates, their use as medicaments and the pharmaceutical compositions containing them. |
| GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
| US7173044B2 (en) * | 2004-02-19 | 2007-02-06 | Solvay Pharmaceuticals B.V. | Imidazoline derivatives having CB1-antagonistic activity |
| US20060030871A1 (en) | 2004-08-05 | 2006-02-09 | Matthew Hain | Vascular tunneler |
| EP1784852A2 (en) * | 2004-08-26 | 2007-05-16 | Philips Intellectual Property & Standards GmbH | Lamp with reflective coating |
| WO2006028226A1 (en) * | 2004-09-09 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Novel imidazolidine derivative and use thereof |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| KR102324567B1 (en) * | 2005-05-13 | 2021-11-09 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Diarylhydantoin compounds |
| DE602005005059D1 (en) * | 2005-05-13 | 2008-04-10 | Protectron Nanocomposites Pte | IMPROVED COLLOIDAL GEL FOR PROTECTIVE TEXTILE SURFACE IMAGES, IMPROVED PROTECTIVE TEXTILE SURFACE PATTERNS AND MANUFACTURING METHOD THEREFOR |
| NZ596260A (en) | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
-
2010
- 2010-02-24 SG SG10201402628VA patent/SG10201402628VA/en unknown
- 2010-02-24 JP JP2011551318A patent/JP2012518661A/en not_active Ceased
- 2010-02-24 SG SG2011061066A patent/SG173837A1/en unknown
- 2010-02-24 CA CA2753425A patent/CA2753425A1/en not_active Abandoned
- 2010-02-24 BR BRPI1007990-4A patent/BRPI1007990A2/en not_active IP Right Cessation
- 2010-02-24 KR KR1020117022048A patent/KR20110130439A/en not_active Application Discontinuation
- 2010-02-24 EP EP10746795.3A patent/EP2400847B1/en not_active Revoked
- 2010-02-24 CN CN2010800179543A patent/CN102421291A/en active Pending
- 2010-02-24 US US13/202,970 patent/US8524755B2/en active Active
- 2010-02-24 WO PCT/US2010/025283 patent/WO2010099238A1/en active Application Filing
- 2010-02-24 AU AU2010218052A patent/AU2010218052A1/en not_active Abandoned
- 2010-02-24 ES ES10746795.3T patent/ES2535466T3/en active Active
- 2010-02-24 RU RU2011139107/04A patent/RU2548918C2/en not_active IP Right Cessation
- 2010-02-24 NZ NZ594741A patent/NZ594741A/en not_active IP Right Cessation
- 2010-02-24 MX MX2011008858A patent/MX2011008858A/en active IP Right Grant
-
2011
- 2011-08-23 IL IL214800A patent/IL214800A0/en unknown
- 2011-08-23 ZA ZA2011/06200A patent/ZA201106200B/en unknown
-
2013
- 2013-05-14 ZA ZA2013/03499A patent/ZA201303499B/en unknown
- 2013-06-24 US US13/925,507 patent/US9023879B2/en active Active
-
2014
- 2014-11-07 JP JP2014227148A patent/JP2015028085A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9023879B2 (en) | 2015-05-05 |
| EP2400847A4 (en) | 2012-08-08 |
| JP2012518661A (en) | 2012-08-16 |
| BRPI1007990A2 (en) | 2015-09-01 |
| KR20110130439A (en) | 2011-12-05 |
| EP2400847A1 (en) | 2012-01-04 |
| RU2011139107A (en) | 2013-04-10 |
| RU2548918C2 (en) | 2015-04-20 |
| MX2011008858A (en) | 2012-01-27 |
| ZA201303499B (en) | 2015-03-25 |
| ZA201106200B (en) | 2013-07-31 |
| ES2535466T3 (en) | 2015-05-11 |
| US20130331421A1 (en) | 2013-12-12 |
| CN102421291A (en) | 2012-04-18 |
| WO2010099238A1 (en) | 2010-09-02 |
| SG173837A1 (en) | 2011-09-29 |
| US8524755B2 (en) | 2013-09-03 |
| EP2400847B1 (en) | 2014-12-17 |
| NZ594741A (en) | 2014-03-28 |
| CA2753425A1 (en) | 2010-09-02 |
| JP2015028085A (en) | 2015-02-12 |
| US20120035231A1 (en) | 2012-02-09 |
| AU2010218052A1 (en) | 2011-09-08 |
| IL214800A0 (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201303499B (en) | Specific diarylhydantoin and diarylthiohydantion compounds | |
| LT3222617T (en) | Psma-targeting compounds and uses thereof | |
| DK3023438T3 (en) | Anti-gitr-antistoffer | |
| DK2457337T3 (en) | Specialtilpasset impuls-burst | |
| GB0919432D0 (en) | Use | |
| EP2462514A4 (en) | Greenbooks | |
| EP2515891A4 (en) | 3-keto-n-propargyl-1-aminoindan | |
| EP2519921A4 (en) | Call-tracking | |
| DK2464943T3 (en) | Systemintegration | |
| GB0922505D0 (en) | Use | |
| GB0902173D0 (en) | Compounds and their use | |
| GB0909768D0 (en) | Novel compounds and uses thereof | |
| GB0922510D0 (en) | Compound and use | |
| EP2470022A4 (en) | Compounds and methods | |
| GB0903348D0 (en) | Compounds and methods relating thereto | |
| GB0905525D0 (en) | Compounds and uses | |
| EP2510125A4 (en) | Hyperprimers | |
| GB0917304D0 (en) | Use | |
| PL387177A1 (en) | Enaminocarbonylic compounds and their application | |
| GB0905231D0 (en) | Compounds and their use | |
| AU4924P (en) | Bonscablue Scaevola aemula | |
| AU4926P (en) | Bonscalib Scaevola aemula | |
| AU4925P (en) | Bonscawi Scaevola aemula | |
| AU4240P (en) | Tuckerbox xTriticosecale | |
| GB0908087D0 (en) | Novel compounds and uses thereof |